Vol 68, No 1 (2017)
Original paper
Published online: 2017-03-01

open access

Page views 1713
Article views/downloads 1930
Get Citation

Connect on Social Media

Connect on Social Media

Epidemiology of gastroenteropancreatic neuroendocrine neoplasms in Krakow and Krakow district in 2007-2011.

Małgorzata Trofimiuk-Müldner, Ewelina Lewkowicz, Katarzyna Wysocka, Dorota Pach, Agnieszka Kiełtyka, Agnieszka Stefańska, Anna Sowa-Staszczak, Romana Tomaszewska, Alicja Hubalewska-Dydejczyk
Pubmed: 28255979
Endokrynol Pol 2017;68(1):42-46.

Abstract

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) are rare and heterogeneous tumours with variable biology. The aim of this study was to evaluate the epidemiology of GEPNEN in the population of Krakow and Krakow district in 2007–2011.

Material and methods: The Database of the Chair and Department of Endocrinology, Jagiellonian University Medical College, comprising the data on NEN cases collected from the Endocrinology Department, University Hospital in Krakow and from independent sources: surgery, pathology, and endocrinology departments located in the Krakow area, was searched for cases of GEPNEN patients living in Krakow and Krakow district, diagnosed between 2007 and 2011. Eighty-eight such patients (39 males, 49 females, median age at diagnosis 59 ± 17 years) were identified and characterised.

Results: The mean follow-up time was 2.67 ± 1.6 years. The most frequent primary location of GEPNEN was small intestine (20%), followed by the appendix (18%), stomach (16%), pancreas (16%), rectum (15%), and colon (15%). NENG1 predominated (64%) in the analysed group. Most well-differentiated GEPNEN (63%) were diagnosed at stage I; however, 18% of them were diagnosed at stage IV. Metastases at diagnosis were found in 31% of patients. The GEPNEN incidence rate in 2007–2011 was 2.1/100000 inhabitants/year, without significant increase during the studied period.

Conclusions: GEPNEN incidence and epidemiology in the population of Krakow and Krakow district is similar to the incidence observed in most European countries. Registers are important tools to evaluate GEPNEN epidemiology. (Endokrynol Pol 2017; 68 (1): 42–46)

Article available in PDF format

View PDF Download PDF file

References

  1. Kos-Kudła B, Blicharz-Dorniak J, Handkiewicz-Junak D, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 418–443.
  2. Salazar R, Wiedenmann B, Rindi G, et al. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology. 2012; 95(2): 71–73.
  3. Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61(1): 6–32.
  4. Fraenkel M, Kim MK, Faggiano A, et al. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26(6): 691–703.
  5. Alsina M, Marcos-Gragera R, Capdevila J, et al. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004. Cancer Epidemiol. 2011; 35(6): e49–e54.
  6. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–3072.
  7. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10): 2655–2664.
  8. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012; 3: 292–302.
  9. van der Zwan JM, Trama A, Otter R, et al. RARECARE WG. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013; 49(11): 2565–2578.
  10. Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res. 2011; 17(3): 759–763.
  11. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010; 17(4): 909–918.
  12. Lim T, Lee J, Kim JJ, et al. Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol. 2011; 7(3): 293–299.
  13. Cho MY, Kim JM, Sohn JH, et al. Gastrointestinal Pathology Study Group of Korean Society of Pathologists. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat. 2012; 44(3): 157–165.
  14. Ploeckinger U, Kloeppel G, Wiedenmann B, et al. representatives of 21 German NET Centers. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009; 90(4): 349–363.
  15. Hubalewska-Dydejczyk A, Trofimiuk M. Diagnostic and therapeutical management of neuroendocrine tumors of unknown origin. In: Kos-Kudła B, ed. Gastroenteropancreatic neuroendocrine tumors.Hubalewska-Dydejczyk A, Trofimiuk M. ed. Via Medica, Gdańsk : 325–342.
  16. Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40(1): 1–18, vii.
  17. Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One. 2013; 8(4): e62487.
  18. Levi F, Te VC, Randimbison L, et al. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer. 2000; 83(7): 952–955.
  19. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001; 92(8): 2204–2210.
  20. Zárate X, Williams N, Herrera MF. Pancreatic incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012; 26(1): 97–103.